Verona Pharma plc (I9SA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Verona Pharma plc (I9SA) has a cash flow conversion efficiency ratio of 0.110x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€30.56 Million ≈ $35.73 Million USD) by net assets (€278.27 Million ≈ $325.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Verona Pharma plc market cap and net worth for the company's overall valuation and market capitalisation.
Verona Pharma plc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Verona Pharma plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Verona Pharma plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verona Pharma plc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Verona Pharma plc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China XD Electric Co Ltd
SHG:601179
|
0.023x |
|
Vibra Energia S.A.
SA:VBBR3
|
0.136x |
|
AVIC Aircraft Co Ltd
SHE:000768
|
0.164x |
|
CareTrust REIT Inc.
NYSE:CTRE
|
0.022x |
|
CubeSmart
NYSE:CUBE
|
0.049x |
|
FREEDOM HLDG DL-001
F:DMW2
|
-0.223x |
|
KT Corporation
NYSE:KT
|
0.034x |
|
Ingenic Semiconductor
SHE:300223
|
0.006x |
Annual Cash Flow Conversion Efficiency for Verona Pharma plc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Verona Pharma plc from 2016 to 2024. View current stock price of Verona Pharma plc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €204.56 Million ≈ $239.15 Million |
€-122.20 Million ≈ $-142.87 Million |
-0.597x | -196.53% |
| 2023-12-31 | €249.28 Million ≈ $291.44 Million |
€-50.22 Million ≈ $-58.71 Million |
-0.201x | +22.44% |
| 2022-12-31 | €230.47 Million ≈ $269.44 Million |
€-59.86 Million ≈ $-69.98 Million |
-0.260x | -15.61% |
| 2021-12-31 | €148.00 Million ≈ $173.03 Million |
€-33.25 Million ≈ $-38.88 Million |
-0.225x | +7.86% |
| 2020-12-31 | €184.85 Million ≈ $216.11 Million |
€-45.08 Million ≈ $-52.70 Million |
-0.244x | +74.74% |
| 2019-12-31 | €44.40 Million ≈ $51.91 Million |
€-42.87 Million ≈ $-50.12 Million |
-0.965x | -325.69% |
| 2018-12-31 | €79.86 Million ≈ $93.36 Million |
€-18.11 Million ≈ $-21.17 Million |
-0.227x | -18.30% |
| 2017-12-31 | €107.95 Million ≈ $126.21 Million |
€-20.70 Million ≈ $-24.20 Million |
-0.192x | -45.96% |
| 2016-12-31 | €42.53 Million ≈ $49.72 Million |
€-5.59 Million ≈ $-6.53 Million |
-0.131x | -- |
About Verona Pharma plc
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more